FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380589767> ?p ?o ?g. }

• W4380589767 endingPage "15" @default.
• W4380589767 startingPage "10" @default.
• W4380589767 abstract "Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has been recommended as third-line treatment agent in non-oncogene driven non-small cell lung cancer (NSCLC). This prospective study aimed to investigate the efficacy and safety of anlotinib plus S-1 for third- or later-line treatment in patients with advanced NSCLC. Methods Patients with histologically or cytologically confirmed NSCLC, and documented disease progression following second-line chemotherapy, and/or epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment were enrolled in this study. The patients were treated anlotinib (8 mg daily d 1-14) and S-1 (60 mg/m 2 d 1-14) and the treatment was repeated every 3 weeks. Treatment was continued until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and adverse events (AEs) were reviewed and evaluated. Results Forty-one patients were enrolled in the study between June 2018 and December 2018. The total ORR and DCR were 26.8% and 80.5%, respectively. The median PFS was 5.2 months [95% confidence interval (CI), 3.9 to 6.6 months]. In the univariate analysis, there was a significant difference in the median PFS between patients with brain metastases and those without brain metastases (4.8 months vs 5.9 months, respectively; P = 0.039). The Eastern Cooperative Oncology Group (ECOG) performance status ( P = 0.002), lines of therapy ( P = 0.015), and therapeutic evaluation ( P = 0.014) were independent factors that influenced PFS. The most common AEs were hypertension, proteinuria, myelosuppression, gastrointestinal reactions, fatigue, and mucositis. Conclusion Anlotinib plus S-1 is an effective and safe regimen for advanced NSCLC as third- or later-line therapy." @default.
• W4380589767 created "2023-06-15" @default.
• W4380589767 creator A5003320613 @default.
• W4380589767 creator A5029594423 @default.
• W4380589767 creator A5030518488 @default.
• W4380589767 creator A5031077714 @default.
• W4380589767 creator A5036575486 @default.
• W4380589767 creator A5037677450 @default.
• W4380589767 creator A5038792983 @default.
• W4380589767 creator A5047539950 @default.
• W4380589767 creator A5069367230 @default.
• W4380589767 creator A5092163098 @default.
• W4380589767 date "2020-02-01" @default.
• W4380589767 modified "2023-10-05" @default.
• W4380589767 title "Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer" @default.
• W4380589767 cites W1972070208 @default.
• W4380589767 cites W2003589574 @default.
• W4380589767 cites W2012516785 @default.
• W4380589767 cites W2037139573 @default.
• W4380589767 cites W2041926998 @default.
• W4380589767 cites W2128885041 @default.
• W4380589767 cites W2132000516 @default.
• W4380589767 cites W2140980839 @default.
• W4380589767 cites W2169262427 @default.
• W4380589767 cites W2567686598 @default.
• W4380589767 cites W2766342472 @default.
• W4380589767 cites W2781525129 @default.
• W4380589767 cites W2791602004 @default.
• W4380589767 cites W2793605704 @default.
• W4380589767 cites W2885503610 @default.
• W4380589767 cites W2889097799 @default.
• W4380589767 cites W2903670823 @default.
• W4380589767 cites W2914358135 @default.
• W4380589767 cites W2952913255 @default.
• W4380589767 cites W4242648511 @default.
• W4380589767 doi "https://doi.org/10.1007/s10330-019-0370-0" @default.
• W4380589767 hasPublicationYear "2020" @default.
• W4380589767 type Work @default.
• W4380589767 citedByCount "0" @default.
• W4380589767 crossrefType "journal-article" @default.
• W4380589767 hasAuthorship W4380589767A5003320613 @default.
• W4380589767 hasAuthorship W4380589767A5029594423 @default.
• W4380589767 hasAuthorship W4380589767A5030518488 @default.
• W4380589767 hasAuthorship W4380589767A5031077714 @default.
• W4380589767 hasAuthorship W4380589767A5036575486 @default.
• W4380589767 hasAuthorship W4380589767A5037677450 @default.
• W4380589767 hasAuthorship W4380589767A5038792983 @default.
• W4380589767 hasAuthorship W4380589767A5047539950 @default.
• W4380589767 hasAuthorship W4380589767A5069367230 @default.
• W4380589767 hasAuthorship W4380589767A5092163098 @default.
• W4380589767 hasConcept C121608353 @default.
• W4380589767 hasConcept C126322002 @default.
• W4380589767 hasConcept C143998085 @default.
• W4380589767 hasConcept C144301174 @default.
• W4380589767 hasConcept C197934379 @default.
• W4380589767 hasConcept C2776256026 @default.
• W4380589767 hasConcept C2776694085 @default.
• W4380589767 hasConcept C2776907518 @default.
• W4380589767 hasConcept C2777802072 @default.
• W4380589767 hasConcept C2778820342 @default.
• W4380589767 hasConcept C2779438470 @default.
• W4380589767 hasConcept C2780739268 @default.
• W4380589767 hasConcept C29730261 @default.
• W4380589767 hasConcept C38180746 @default.
• W4380589767 hasConcept C71924100 @default.
• W4380589767 hasConcept C90924648 @default.
• W4380589767 hasConceptScore W4380589767C121608353 @default.
• W4380589767 hasConceptScore W4380589767C126322002 @default.
• W4380589767 hasConceptScore W4380589767C143998085 @default.
• W4380589767 hasConceptScore W4380589767C144301174 @default.
• W4380589767 hasConceptScore W4380589767C197934379 @default.
• W4380589767 hasConceptScore W4380589767C2776256026 @default.
• W4380589767 hasConceptScore W4380589767C2776694085 @default.
• W4380589767 hasConceptScore W4380589767C2776907518 @default.
• W4380589767 hasConceptScore W4380589767C2777802072 @default.
• W4380589767 hasConceptScore W4380589767C2778820342 @default.
• W4380589767 hasConceptScore W4380589767C2779438470 @default.
• W4380589767 hasConceptScore W4380589767C2780739268 @default.
• W4380589767 hasConceptScore W4380589767C29730261 @default.
• W4380589767 hasConceptScore W4380589767C38180746 @default.
• W4380589767 hasConceptScore W4380589767C71924100 @default.
• W4380589767 hasConceptScore W4380589767C90924648 @default.
• W4380589767 hasLocation W43805897671 @default.
• W4380589767 hasOpenAccess W4380589767 @default.
• W4380589767 hasPrimaryLocation W43805897671 @default.
• W4380589767 hasRelatedWork W1985488488 @default.
• W4380589767 hasRelatedWork W2008545061 @default.
• W4380589767 hasRelatedWork W2060263774 @default.
• W4380589767 hasRelatedWork W2401649272 @default.
• W4380589767 hasRelatedWork W2978946191 @default.
• W4380589767 hasRelatedWork W3031381806 @default.
• W4380589767 hasRelatedWork W3207524449 @default.
• W4380589767 hasRelatedWork W3211406726 @default.
• W4380589767 hasRelatedWork W4309213401 @default.
• W4380589767 hasRelatedWork W4317566941 @default.
• W4380589767 isParatext "false" @default.
• W4380589767 isRetracted "false" @default.
• W4380589767 workType "article" @default.